Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial
详细信息 查看全文
- 作者：Eric H. Decloedt ; Maia Lesosky ; Gary Maartens ; John A. Joska
- 关键词：South Africa ; Randomised placebo ; controlled clinical trial ; HIV ; associated neurocognitive impairment ; HIV ; Lithium ; Placebo ; Antiretroviral therapy ; Tenofovir
- 刊名：AIDS Research and Therapy
- 出版年：2017
- 出版时间：December 2017
- 年：2017
- 卷：14
- 期：1
- 全文大小：880KB
- 刊物主题：Infectious Diseases; Virology;
- 出版者：BioMed Central
- ISSN：1742-6405
- 卷排序：14
文摘
BackgroundThe prevalence of bipolar disorder in HIV-infected patients is higher than the general population. Lithium is the most effective mood stabiliser, while tenofovir disoproxil fumarate (TDF) is frequently used as part of combination antiretroviral therapy (ART). Both TDF and lithium are associated with renal tubular toxicity, which could be additive, or a pharmacokinetic interaction may occur at renal transporters with a decrease in TDF elimination.